Efficacy and Safety of Risankizumab Compared with Apremilast in Patients with Moderate Plaque Psoriasis: Mean PASI and BSA Results From the Phase 4 IMMpulse Trial. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 7, n. 6, p. s257, 2023. DOI: 10.25251/skin.7.supp.257. Disponível em: https://skin.dermsquared.com/skin/article/view/2404. Acesso em: 19 apr. 2025.